Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN4ZKC)

• Drug Name: PARAOXON Drug Info
• Synonyms: PARAOXON; Phosphacol; Diethyl paraoxon; 311-45-5; Ethyl paraoxon; Diethyl 4-nitrophenyl phosphate; Phosphachole; Mintacol; Paraoxone; Miotisal; Fosfakol; Phosphakol; Oxyparathion; Chinorto; Diethyl p-nitrophenyl phosphate; Paroxan; Mintaco; Chinorta; Eticol; Miotisal A; Diethylparaoxon; Soluglaucit; Soluglacit; Paraoxon-ethyl; Ethyl paraoxan; p-Nitrophenyl diethyl phosphate; Phosphoric acid, diethyl 4-nitrophenyl ester; Ester 25; Pestox 101; E 600 (pesticide); Diethyl-p-nitrophenyl phosphate; Phosphoric acid diethyl 4-nitrophenyl ester

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9395
  ChEBI ID: CHEMBL23838
  CAS Number: CAS 311-45-5
  TTD Drug ID: DMN4ZKC
  INTEDE Drug ID: DR1241

Molecule-Related Drug Atlas

Drug(s) Targeting Fatty acid amide hydrolase (FAAH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[11]
Thiopental	DMGP8AX	Anaesthesia	9A78.6	Approved	[12]
JNJ-42165279	DM72GZO	Anxiety disorder	6B00-6B0Z	Phase 2	[13]
SSR411298	DMGTB2Q	Major depressive disorder	6A70.3	Phase 2	[14]
IW-6118	DMP42W1	Inflammation	1A00-CA43.1	Phase 2	[15]
PF-04457845	DMPRYU1	Liver disease	DB90-BD99	Phase 2	[16]
IPI-940	DMEIM5G	Pain	MG30-MG3Z	Phase 1	[17]
PMID29053063-Compound-11d	DMDRK68	N. A.	N. A.	Patented	[18]
Piperazine carbamic compound 1	DMZSYU4	N. A.	N. A.	Patented	[18]
Piperazine carbamic compound 2	DMMQ0ZO	N. A.	N. A.	Patented	[18]

Drug(s) Targeting Carbonic anhydrase I (CA-I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[19]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[20]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[20]
Methazolamide	DM7J2TA	Glaucoma/ocular hypertension	9C61	Approved	[21]
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[20]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[22]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[23]
CG-100649	DMIKMA9	Arthritis	FA20	Phase 3	[24]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[22]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[25]

Drug(s) Targeting Carbonic anhydrase II (CA-II)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[19]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[26]
Dorzolamide	DMA17D0	Ocular hypertension	9C61.01	Approved	[27]
Chlorothiazide	DMLHESP	Chronic heart failure	BD1Z	Approved	[28]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[29]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[29]
Cyclothiazide	DMJ4AWC	Congestive heart failure	BD10	Approved	[30]
Ethinamate	DMK57GB	Insomnia	7A00-7A0Z	Approved	[31]
Benzthiazide	DMQWZ0H	High blood pressure	BA00	Approved	[32]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[22]

Drug(s) Targeting Acetylcholinesterase (AChE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[33]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[34]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[35]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[36]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[37]
Neostigmine	DM6T2J3	Myasthenia gravis	8C6Y	Approved	[38]
YM443	DMNZCI1	Functional dyspepsia	DD90.3	Approved	[39]
Ambenonium	DMOP0BL	Myasthenia gravis	8C6Y	Approved	[40]
Demecarium bromide	DMAYEU1	Open-angle glaucoma	9C61	Approved	[41]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[42]

Drug(s) Targeting Carbonic anhydrase (CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[43]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[44]
Quinethazone	DMWCOSR	Hypertension	BA00-BA04	Approved	[45]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[22]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[23]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[22]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[25]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[46]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[23]
PMID30074415-Compound-21	DM3NPOU	N. A.	N. A.	Patented	[47]

Drug(s) Targeting Cannabinoid receptor 1 (CB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[48]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[49]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[50]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[51]
Tebipenem	DMVSX6O	Urinary tract infection	GC08	Phase 3	[52]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[53]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[54]
SR-147778	DMNAECP	Obesity	5B81	Phase 2	[55]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[56]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[57]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[58]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[59]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[60]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[61]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[62]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[63]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[64]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[65]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[59]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[66]

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[67]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[68]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[69]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[70]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[71]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[64]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[73]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[74]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[75]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[76]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[77]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[78]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[79]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[80]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[81]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[82]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[83]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[84]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[79]

Drug(s) Metabolized By Cytochrome P450 2E1 (CYP2E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[85]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[86]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[87]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[88]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[89]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[73]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[90]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[91]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[92]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[93]

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[67]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[94]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[94]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[90]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[95]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[96]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[97]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[94]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[98]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[99]

Drug(s) Metabolized By Serum paraoxonase/arylesterase 1 (PON1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Loteprednol Etabonate	DM8QTJI	Eye inflammation	9A02	Approved	[100]
Prulifloxacin	DMOK965	Urinary tract infection	GC08	Approved	[7]
RTR-003632	DM45NHF	N. A.	N. A.	Phase 2	[6]
gamma-butyrolactone	DMDCZWY	Discovery agent	N.A.	Investigative	[6]
Coumaranone	DM7TCPG	N. A.	N. A.	Investigative	[6]
Dihydrocoumarin	DMGLX1R	N. A.	N. A.	Investigative	[6]
Gamma-thiobutyrolactone	DM83HUI	N. A.	N. A.	Investigative	[6]
Homogentisic acid	DMQD0YW	N. A.	N. A.	Investigative	[6]

Drug(s) Affected By Patatin-like phospholipase domain-containing protein 6 (PNPLA6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[101]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[103]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[104]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[104]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[107]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[108]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]

Drug(s) Affected By Cocaine esterase (CES2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[110]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[111]
Dextropropoxyphene	DM23HCX	Pain	MG30-MG3Z	Approved	[112]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[115]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[116]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[118]
Cantharidin	DMBP5N3	Molluscum contagiosum infection	1E76	Approved	[119]

Drug(s) Affected By Protein c-Fos (FOS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[120]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[121]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[122]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[121]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[123]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[124]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[125]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[126]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[127]

Drug(s) Affected By Phospholipid-transporting ATPase ABCA1 (ABCA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[128]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[129]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[130]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[131]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[132]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[133]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[134]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[135]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[136]

Drug(s) Affected By Transforming growth factor beta-1 proprotein (TGFB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[137]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[138]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[139]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[140]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[141]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[142]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[143]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[144]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[145]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[146]

Drug(s) Affected By Superoxide dismutase , mitochondrial (SOD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[147]
Selenium	DM25CGV	N. A.	N. A.	Approved	[148]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[149]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[150]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[151]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[152]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[153]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[131]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[154]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[155]

Drug(s) Affected By Histone H2A type 1-B/E (H2AC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[156]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[157]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[158]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[159]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[160]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[161]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[108]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[162]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[163]

Drug(s) Affected By ATP synthase subunit beta, mitochondrial (ATP5F1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[164]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[157]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[165]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[166]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[167]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[168]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[170]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[167]

Drug(s) Affected By Alpha-enolase (ENO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[171]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[165]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[172]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[173]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[131]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[174]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[175]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[176]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[177]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[104]

Drug(s) Affected By Heat shock protein HSP 90-alpha (HSP90AA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[178]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[179]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[180]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[181]
Selenium	DM25CGV	N. A.	N. A.	Approved	[101]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[182]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[183]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[184]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]

Drug(s) Affected By Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[185]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[174]
Tetracaine	DM9J6C2	Spinal anesthesia	MB40.3	Approved	[186]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[187]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[118]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[188]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[189]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[107]

Drug(s) Affected By Heat shock protein HSP 90-beta (HSP90AB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[190]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[191]
Selenium	DM25CGV	N. A.	N. A.	Approved	[101]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[165]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[183]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[192]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[193]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[175]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]

Drug(s) Affected By Synaptophysin (SYP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[124]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[194]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[159]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[195]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[194]
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[196]
Methamphetamine	DMPM4SK	Anxiety		Approved	[197]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[198]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[199]

Drug(s) Affected By Glutathione S-transferase theta-2 (GSTT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[200]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[201]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[202]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[162]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[203]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[204]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[205]
Artesunate	DMR27C8	Infection of P. falciparum	1F40	Approved	[206]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[207]

Drug(s) Affected By Neurofilament heavy polypeptide (NEFH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[120]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[174]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[208]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[209]
Scopolamine	DMOM8AL	Addictive disorder	6C50-6C5Z	Approved	[210]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[162]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[211]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[163]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[212]

Drug(s) Affected By Glutathione S-transferase Mu 2 (GSTM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[213]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[214]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[215]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[215]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[107]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[216]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[217]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[218]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]

Drug(s) Affected By Bone morphogenetic protein 8B (BMP8B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[219]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[220]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[221]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[220]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[222]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[223]

Drug(s) Affected By Lysosomal acid lipase/cholesteryl ester hydrolase (LIPA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Haloperidol	DM96SE0	Delirium		Approved	[224]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[187]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[219]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[224]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[224]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[225]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[162]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[163]

Drug(s) Affected By C-X-C motif chemokine 5 (CXCL5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[226]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[227]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[228]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[229]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[103]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[188]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[230]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[200]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[231]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[232]

Drug(s) Affected By Rho GDP-dissociation inhibitor 1 (ARHGDIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[124]
Selenium	DM25CGV	N. A.	N. A.	Approved	[101]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[165]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[233]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[234]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[235]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[236]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[188]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[114]

Drug(s) Affected By Pancreatic lipase-related protein 2 (PNLIPRP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[168]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[162]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[237]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[220]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[222]
acetaldehyde	DMJFKG4	Discovery agent	N.A.	Investigative	[238]

Drug(s) Affected By Actin, cytoplasmic 1 (ACTB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[124]
Selenium	DM25CGV	N. A.	N. A.	Approved	[101]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[165]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[214]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[239]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[240]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[114]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]

Drug(s) Affected By Histone H4 (H4C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[156]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[241]
Selenium	DM25CGV	N. A.	N. A.	Approved	[101]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[242]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[243]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[214]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[244]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[229]

Drug(s) Affected By Tropomyosin alpha-4 chain (TPM4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[223]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[245]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[240]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[114]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[246]

Drug(s) Affected By Protein SET (SET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[214]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[247]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[187]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[248]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[248]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[188]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[249]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[250]

Drug(s) Affected By A-kinase anchor protein 12 (AKAP12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[251]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[252]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[155]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[228]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[253]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[254]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[215]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[255]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[240]

Drug(s) Affected By Lamin-B2 (LMNB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[187]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[162]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[256]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[257]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[258]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[259]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[260]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[261]

Drug(s) Affected By Interleukin enhancer-binding factor 2 (ILF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[214]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[157]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[262]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[263]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[262]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[264]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[265]
COUMESTROL	DM40TBU	Discovery agent	N.A.	Investigative	[266]

Drug(s) Affected By Protein-tyrosine kinase 2-beta (PTK2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[267]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[193]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[268]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[269]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[202]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[270]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[271]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[272]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[221]

Drug(s) Affected By Histone H2B type 2-E (H2BC21)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[243]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[155]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[158]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[273]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[161]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[231]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[202]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[108]

Drug(s) Affected By Acyl-CoA-binding domain-containing protein 5 (ACBD5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[157]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[240]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[274]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[272]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[275]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[275]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[222]

Drug(s) Affected By Pecanex-like protein 4 (PCNX4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[159]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[188]
Bortezomib	DMNO38U	Leukemia		Approved	[276]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[162]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[272]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[222]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[265]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[277]

Drug(s) Affected By Kin of IRRE-like protein 2 (KIRREL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[278]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[202]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[162]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[221]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[222]
acetaldehyde	DMJFKG4	Discovery agent	N.A.	Investigative	[238]

Drug(s) Affected By Stearoyl-CoA desaturase 5 (SCD5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[174]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[160]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[161]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[231]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[198]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[264]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[222]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[279]
Ganoderic acid A	DM42EVG	Discovery agent	N.A.	Investigative	[280]

Drug(s) Affected By Immunoglobulin-like domain-containing receptor 1 (ILDR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[255]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[222]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[281]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[161]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[282]

Drug(s) Affected By RING finger protein 113B (RNF113B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[222]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[279]

Drug(s) Affected By Tetratricopeptide repeat protein 16 (TTC16)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]

Drug(s) Affected By Histone H2A type 1-H (H2AC12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[156]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[283]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[284]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[285]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[162]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[163]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[286]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[257]
Lucanthone	DMZLBUO	Solid tumour/cancer	2A00-2F9Z	Approved	[287]

Drug(s) Affected By Glutamate decarboxylase 1 (GAD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[174]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[288]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[228]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[240]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[159]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[289]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[290]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[291]

Drug(s) Affected By Linker for activation of T-cells family member 2 (LAT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[233]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[292]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[215]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[215]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[107]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[162]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[293]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[294]
Mivebresib	DMCPF90	Acute myeloid leukaemia	2A60	Phase 1	[295]

Drug(s) Affected By Coiled-coil domain-containing protein 177 (CCDC177)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[174]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[228]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[228]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[222]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[296]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[228]

Drug(s) Affected By Protein mono-ADP-ribosyltransferase PARP4 (PARP4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[185]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[254]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[240]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[169]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[162]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[274]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[297]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[272]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[298]

Drug(s) Affected By Axin-2 (AXIN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[114]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[228]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[299]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[188]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[200]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[300]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[107]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[301]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[162]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[302]

Drug(s) Affected By Albumin (ALB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[274]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[138]
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[303]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[304]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[305]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[306]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[307]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[308]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[309]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[310]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[2]
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Inhibitor	[1]
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[3]
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[3]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[3]
Fatty acid amide hydrolase (FAAH)	TTDP1UC	NOUNIPROTAC	Inhibitor	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[4]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[5]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[4]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[4]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[4]
Serum paraoxonase/arylesterase 1 (PON1)	DESDN74	PON1_HUMAN	Substrate	[6]
Serum paraoxonase/arylesterase 2 (PON2)	DEHJU7E	PON2_HUMAN	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
A-kinase anchor protein 12 (AKAP12)	OTCVRDDX	AKA12_HUMAN	Gene/Protein Processing	[8]
Abscission/NoCut checkpoint regulator	OT6V9IDI	ANCHR_HUMAN	Gene/Protein Processing	[9]
Actin, cytoplasmic 1 (ACTB)	OT1MCP2F	ACTB_HUMAN	Gene/Protein Processing	[9]
Acyl-CoA-binding domain-containing protein 5 (ACBD5)	OT7L16DY	ACBD5_HUMAN	Gene/Protein Processing	[8]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Drug Response	[10]
Alpha-enolase (ENO1)	OTB1KWJS	ENOA_HUMAN	Gene/Protein Processing	[9]
ATP synthase subunit beta, mitochondrial (ATP5F1B)	OTLFZUQK	ATPB_HUMAN	Gene/Protein Processing	[9]
Axin-2 (AXIN2)	OTRMGQNU	AXIN2_HUMAN	Gene/Protein Processing	[8]
Bone morphogenetic protein 8B (BMP8B)	OTJC3AB9	BMP8B_HUMAN	Gene/Protein Processing	[8]
C-X-C motif chemokine 5 (CXCL5)	OTZOUPCA	CXCL5_HUMAN	Gene/Protein Processing	[8]

References

• [1] Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
• [2] Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
• [3] Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12.
• [4] Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
• [5] Interaction of ethanol and the organophosphorus insecticide parathion. Biochem Pharmacol. 1995 Nov 27;50(11):1925-32.
• [6] Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000 Nov;28(11):1335-42.
• [7] Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
• [8] Genomic and phenotypic alterations of the neuronal-like cells derived from human embryonal carcinoma stem cells (NT2) caused by exposure to organophosphorus compounds paraoxon and mipafox. Int J Mol Sci. 2014 Jan 9;15(1):905-26. doi: 10.3390/ijms15010905.
• [9] Paraoxon-induced protein expression changes to SH-SY5Y cells. Chem Res Toxicol. 2010 Nov 15;23(11):1656-62. doi: 10.1021/tx100192f. Epub 2010 Oct 8.
• [10] Serum albumins and detoxication of anti-cholinesterase agents. Chem Biol Interact. 2010 Sep 6;187(1-3):325-9. doi: 10.1016/j.cbi.2010.03.001. Epub 2010 Mar 6.
• [11] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [12] The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [15] The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
• [16] Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
• [18] A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
• [19] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [20] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
• [22] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [23] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [24] Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
• [25] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [26] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [27] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [28] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [29] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [30] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [31] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [32] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [33] Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [35] Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
• [36] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [37] Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
• [38] Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
• [39] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [40] Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
• [41] The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
• [42] Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
• [43] Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
• [44] Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
• [45] Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
• [46] Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
• [47] Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
• [48] Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
• [49] Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
• [50] Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
• [51] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [52] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [53] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [54] Company report (Gwpharm)
• [55] Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
• [56] Clinical pipeline report, company report or official report of Bird Rock Bio.
• [57] Clinical pipeline report, company report or official report of Affimed Therapeutics.
• [58] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [59] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [60] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [61] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [62] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [63] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [64] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [65] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [66] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [67] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [68] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [69] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [70] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [71] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [72] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [73] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [74] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [75] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [76] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [77] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [78] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [79] Drug Interactions Flockhart Table
• [80] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [81] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [82] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [83] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [84] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [85] Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
• [86] Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
• [87] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [88] Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
• [89] A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
• [90] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [91] Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
• [92] Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
• [93] CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
• [94] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [95] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [96] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [97] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [98] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [99] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [100] Identification of esterase involved in the metabolism of two corticosteroid soft drugs. Biochem Pharmacol. 2017 Mar 1;127:82-89.
• [101] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [102] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [103] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [104] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [105] Constructs of human neuropathy target esterase catalytic domain containing mutations related to motor neuron disease have altered enzymatic properties. Toxicol Lett. 2010 Jul 1;196(2):67-73. doi: 10.1016/j.toxlet.2010.03.1120. Epub 2010 Apr 9.
• [106] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [107] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [108] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [109] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [110] Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos. 2000 Feb;28(2):186-91.
• [111] Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway. Cancer Biol Ther. 2006 Nov;5(11):1450-6.
• [112] Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther. 1999 Jul;290(1):314-8.
• [113] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [114] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [115] Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. Chem Biol Interact. 2013 Mar 25;203(1):226-30.
• [116] Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol Sci. 2007 Jan;95(1):13-22.
• [117] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [118] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [119] Hepatoxicity mechanism of cantharidin-induced liver LO2 cells by LC-MS metabolomics combined traditional approaches. Toxicol Lett. 2020 Oct 15;333:49-61. doi: 10.1016/j.toxlet.2020.07.024. Epub 2020 Jul 26.
• [120] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [121] Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
• [122] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [123] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [124] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [125] Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014 Jan 20;16(1):R17. doi: 10.1186/ar4444.
• [126] Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
• [127] The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004 Jun 25;279(26):27008-16. doi: 10.1074/jbc.M403588200. Epub 2004 Apr 16.
• [128] Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008 Dec;58(12):3675-83.
• [129] Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res. 2009 May 1;15(9):3076-83. doi: 10.1158/1078-0432.CCR-08-3004. Epub 2009 Apr 21.
• [130] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [131] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [132] Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
• [133] Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist. Biochem Pharmacol. 2010 May 1;79(9):1310-6. doi: 10.1016/j.bcp.2009.12.018. Epub 2010 Jan 8.
• [134] Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid. J Lipid Res. 2019 Apr;60(4):794-804. doi: 10.1194/jlr.M088880. Epub 2019 Feb 1.
• [135] Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I. Biochem Biophys Res Commun. 2005 Jun 17;331(4):1533-41. doi: 10.1016/j.bbrc.2005.04.071.
• [136] Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1228-36. doi: 10.1161/ATVBAHA.110.205500. Epub 2010 Mar 25.
• [137] Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002 Oct;40(4):625-31.
• [138] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [139] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [140] Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res. 2010 Feb 15;70(4):1314-22. doi: 10.1158/0008-5472.CAN-09-3292. Epub 2010 Feb 9.
• [141] PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells. Antioxid Redox Signal. 2002 Dec;4(6):877-84. doi: 10.1089/152308602762197416.
• [142] Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
• [143] Cytokine abnormalities in a patient with eosinophilic fasciitis. Ann Allergy Asthma Immunol. 2003 Apr;90(4):452-5. doi: 10.1016/S1081-1206(10)61832-7.
• [144] Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br J Pharmacol. 2009 Jun;157(3):362-70. doi: 10.1111/j.1476-5381.2009.00161.x. Epub 2009 Apr 9.
• [145] Enhanced apoptosis and transforming growth factor-beta1 expression in colorectal adenomas and carcinomas after Sulindac therapy. Dis Colon Rectum. 2001 Jul;44(7):1008-15. doi: 10.1007/BF02235490.
• [146] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [147] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [148] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [149] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [150] P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
• [151] Epinephrine upregulates superoxide dismutase in human coronary artery endothelial cells. Free Radic Biol Med. 2001 Jan 15;30(2):148-53.
• [152] Cissus quadrangularis ethanol extract upregulates superoxide dismutase, glutathione peroxidase and endothelial nitric oxide synthase expression in hydrogen peroxide-injured human ECV304 cells. J Ethnopharmacol. 2012 Sep 28;143(2):664-72.
• [153] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [154] Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
• [155] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [156] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [157] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [158] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [159] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [160] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [161] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [162] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [163] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [164] Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol. 2010 May;24(5):969-80. doi: 10.1210/me.2009-0148. Epub 2010 Mar 8.
• [165] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [166] Biotinylated quercetin as an intrinsic photoaffinity proteomics probe for the identification of quercetin target proteins. Bioorg Med Chem. 2011 Aug 15;19(16):4710-20. doi: 10.1016/j.bmc.2011.07.005. Epub 2011 Jul 13.
• [167] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [168] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [169] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [170] Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol In Vitro. 2010 Sep;24(6):1696-704. doi: 10.1016/j.tiv.2010.05.017. Epub 2010 May 26.
• [171] Oxidative modifications of proteins by sodium arsenite in human umbilical vein endothelial cells. Environ Toxicol. 2011 Oct;26(5):459-71. doi: 10.1002/tox.20572. Epub 2010 Mar 1.
• [172] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [173] Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines. Toxicol Appl Pharmacol. 2007 Apr 15;220(2):197-210. doi: 10.1016/j.taap.2006.12.030. Epub 2007 Jan 9.
• [174] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [175] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [176] Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
• [177] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [178] Arsenic trioxide (As(2)O(3)) induced apoptosis and its mechanisms in a human esophageal squamous carcinoma cell line. Chin Med J (Engl). 2002 Feb;115(2):280-5.
• [179] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [180] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [181] Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
• [182] Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006 Oct;188(2):265-73. doi: 10.1016/j.atherosclerosis.2005.10.045. Epub 2005 Dec 20.
• [183] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [184] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [185] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [186] Tetracaine hydrochloride induces cell cycle arrest in melanoma by downregulating hnRNPA1. Toxicol Appl Pharmacol. 2022 Jan 1;434:115810. doi: 10.1016/j.taap.2021.115810. Epub 2021 Nov 23.
• [187] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [188] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [189] Folic acid induces cell type-specific changes in the transcriptome of breast cancer cell lines: a proof-of-concept study. J Nutr Sci. 2016 Apr 26;5:e17. doi: 10.1017/jns.2016.8. eCollection 2016.
• [190] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [191] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [192] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [193] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [194] Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023 Mar 15;487:153461. doi: 10.1016/j.tox.2023.153461. Epub 2023 Feb 16.
• [195] The induction of cytochrome P450 2E1 by ethanol leads to the loss of synaptic proteins via PPARalpha down-regulation. Toxicology. 2017 Jun 15;385:18-27.
• [196] The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells. Int J Cancer. 2009 Jul 1;125(1):235-43. doi: 10.1002/ijc.24331.
• [197] Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):467-74. doi: 10.1097/00126334-200312150-00004.
• [198] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [199] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [200] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [201] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [202] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [203] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [204] Human drug metabolism genes in parathion-and estrogen-treated breast cells. Int J Mol Med. 2007 Dec;20(6):875-81.
• [205] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [206] Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. In Vivo. 2005 Jan-Feb;19(1):225-32.
• [207] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [208] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [209] Tryptanthrin induces growth inhibition and neuronal differentiation in the human neuroblastoma LA-N-1 cells. Chem Biol Interact. 2013 Apr 25;203(2):512-21. doi: 10.1016/j.cbi.2013.03.001. Epub 2013 Mar 13.
• [210] Protective role of Ashwagandha leaf extract and its component withanone on scopolamine-induced changes in the brain and brain-derived cells. PLoS One. 2011;6(11):e27265. doi: 10.1371/journal.pone.0027265. Epub 2011 Nov 11.
• [211] Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006 Dec 1;66(23):11187-93. doi: 10.1158/0008-5472.CAN-06-1274.
• [212] Arsenic metabolites affect expression of the neurofilament and tau genes: an in-vitro study into the mechanism of arsenic neurotoxicity. Toxicol In Vitro. 2007 Sep;21(6):1104-12. doi: 10.1016/j.tiv.2007.04.007. Epub 2007 Apr 27.
• [213] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [214] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [215] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [216] Astaxanthin and omega-3 fatty acids individually and in combination protect against oxidative stress via the Nrf2-ARE pathway. Food Chem Toxicol. 2013 Dec;62:869-75.
• [217] Simulation of interindividual differences in inactivation of reactive para-benzoquinone imine metabolites of diclofenac by glutathione S-transferases in human liver cytosol. Toxicol Lett. 2016 Jul 25;255:52-62.
• [218] Expression of glutathione S-transferase M2 in stage I/II non-small cell lung cancer and alleviation of DNA damage exposure to benzo[a]pyrene. Toxicol Lett. 2010 Feb 15;192(3):316-23. doi: 10.1016/j.toxlet.2009.11.003. Epub 2009 Nov 10.
• [219] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [220] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [221] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [222] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [223] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [224] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [225] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [226] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [227] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [228] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [229] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [230] Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses. Immunology. 2007 Jun;121(2):266-75. doi: 10.1111/j.1365-2567.2007.02574.x. Epub 2007 Mar 7.
• [231] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [232] Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene. 2010 Sep 16;29(37):5159-70. doi: 10.1038/onc.2010.255. Epub 2010 Jun 21.
• [233] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [234] Using a customized DNA microarray for expression profiling of the estrogen-responsive genes to evaluate estrogen activity among natural estrogens and industrial chemicals. Environ Health Perspect. 2004 May;112(7):773-81. doi: 10.1289/ehp.6753.
• [235] [Differential proteomic expression in human liver cells stimulated by hydroquinone]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2006 Nov;24(11):658-61.
• [236] Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
• [237] Further biochemical characterization of human pancreatic lipase-related protein 2 expressed in yeast cells. J Lipid Res. 2007 Jul;48(7):1539-49. doi: 10.1194/jlr.M600486-JLR200. Epub 2007 Mar 30.
• [238] Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
• [239] Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. Eur J Pharmacol. 2002 Aug 9;449(3):197-205.
• [240] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [241] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [242] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [243] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [244] A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):904-12. doi: 10.1016/j.ijrobp.2008.10.032.
• [245] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [246] Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring). 2010 Jan;18(1):27-34. doi: 10.1038/oby.2009.208. Epub 2009 Jun 25.
• [247] Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol. 2003 May;85(1):1-8. doi: 10.1016/s0960-0760(03)00142-0.
• [248] The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
• [249] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [250] Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. Proteomics. 2009 Apr;9(7):1952-66. doi: 10.1002/pmic.200701089.
• [251] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [252] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [253] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [254] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [255] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [256] New insights into the mechanisms underlying 5-fluorouracil-induced intestinal toxicity based on transcriptomic and metabolomic responses in human intestinal organoids. Arch Toxicol. 2021 Aug;95(8):2691-2718. doi: 10.1007/s00204-021-03092-2. Epub 2021 Jun 20.
• [257] Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
• [258] Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol Cell Proteomics. 2011 Jan;10(1):M110.002170.
• [259] Proteomic analysis of the cellular response to a potent sensitiser unveils the dynamics of haptenation in living cells. Toxicology. 2020 Dec 1;445:152603. doi: 10.1016/j.tox.2020.152603. Epub 2020 Sep 28.
• [260] Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. doi: 10.1002/cam4.1179. Epub 2017 Sep 27.
• [261] Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
• [262] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [263] Comparative proteomics reveals concordant and discordant biochemical effects of caffeine versus epigallocatechin-3-gallate in human endothelial cells. Toxicol Appl Pharmacol. 2019 Sep 1;378:114621. doi: 10.1016/j.taap.2019.114621. Epub 2019 Jun 10.
• [264] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [265] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [266] Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
• [267] Discovery of a novel compound: insight into mechanisms for acrylamide-induced axonopathy and colchicine-induced apoptotic neuronal cell death. Brain Res. 2001 Aug 3;909(1-2):8-19. doi: 10.1016/s0006-8993(01)02608-7.
• [268] Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments. J Huazhong Univ Sci Technolog Med Sci. 2017 Aug;37(4):621-627. doi: 10.1007/s11596-017-1781-1. Epub 2017 Aug 8.
• [269] Positive signaling interactions between arsenic and ethanol for angiogenic gene induction in human microvascular endothelial cells. Toxicol Sci. 2008 Apr;102(2):319-27. doi: 10.1093/toxsci/kfn003. Epub 2008 Jan 8.
• [270] Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003 Jun;81(6):543-55.
• [271] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [272] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [273] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [274] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [275] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [276] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [277] A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302. doi: 10.1371/journal.pone.0178302. eCollection 2017.
• [278] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [279] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [280] Ganoderic Acid A improves high fat diet-induced obesity, lipid accumulation and insulin sensitivity through regulating SREBP pathway. Chem Biol Interact. 2018 Jun 25;290:77-87.
• [281] Characterization of the Molecular Alterations Induced by the Prolonged Exposure of Normal Colon Mucosa and Colon Cancer Cells to Low-Dose Bisphenol A. Int J Mol Sci. 2022 Oct 1;23(19):11620. doi: 10.3390/ijms231911620.
• [282] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [283] In vitro effects of aldehydes present in tobacco smoke on gene expression in human lung alveolar epithelial cells. Toxicol In Vitro. 2013 Apr;27(3):1072-81.
• [284] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [285] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [286] RNA sequence analysis of inducible pluripotent stem cell-derived cardiomyocytes reveals altered expression of DNA damage and cell cycle genes in response to doxorubicin. Toxicol Appl Pharmacol. 2018 Oct 1;356:44-53.
• [287] Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011 Feb 25;286(8):6602-13.
• [288] DNA methyltransferase inhibitors coordinately induce expression of the human reelin and glutamic acid decarboxylase 67 genes. Mol Pharmacol. 2007 Mar;71(3):644-53. doi: 10.1124/mol.106.030635. Epub 2006 Oct 25.
• [289] Decarboxylases as hypothetical targets for actions of organophosphates: Molecular modeling for prediction of hidden and unexpected health threats. Food Chem Toxicol. 2022 Mar;161:112856. doi: 10.1016/j.fct.2022.112856. Epub 2022 Feb 11.
• [290] Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
• [291] Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci. 2007 Oct 17;27(42):11254-62. doi: 10.1523/JNEUROSCI.3272-07.2007.
• [292] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [293] NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. Sci Rep. 2020 Jun 25;10(1):10315. doi: 10.1038/s41598-020-66223-2.
• [294] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [295] Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS One. 2022 Apr 29;17(4):e0266966. doi: 10.1371/journal.pone.0266966. eCollection 2022.
• [296] Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicol Appl Pharmacol. 2019 Dec 15;385:114814. doi: 10.1016/j.taap.2019.114814. Epub 2019 Nov 9.
• [297] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [298] Characterizing the genetic basis for nicotine induced cancer development: a transcriptome sequencing study. PLoS One. 2013 Jun 18;8(6):e67252.
• [299] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [300] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [301] Estrogen receptor alpha (ER)-mediated coregulator binding and gene expression discriminates the toxic ER agonist diethylstilbestrol (DES) from the endogenous ER agonist 17-estradiol (E2). Cell Biol Toxicol. 2020 Oct;36(5):417-435. doi: 10.1007/s10565-020-09516-6. Epub 2020 Feb 22.
• [302] A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
• [303] A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
• [304] The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
• [305] Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
• [306] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [307] Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
• [308] [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
• [309] Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
• [310] Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.